191 related articles for article (PubMed ID: 24817940)
1. AKT/ERK activation is associated with gastric cancer cell resistance to paclitaxel.
Wu G; Qin XQ; Guo JJ; Li TY; Chen JH
Int J Clin Exp Pathol; 2014; 7(4):1449-58. PubMed ID: 24817940
[TBL] [Abstract][Full Text] [Related]
2. Circular RNA PLEC acts as a sponge of microRNA-198 to promote gastric carcinoma cell resistance to paclitaxel and tumorigenesis.
Zhou N; Wang W; Xu C; Yu W
Pathol Res Pract; 2021 Aug; 224():153487. PubMed ID: 34225215
[TBL] [Abstract][Full Text] [Related]
3. Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway.
Chen D; Lin X; Zhang C; Liu Z; Chen Z; Li Z; Wang J; Li B; Hu Y; Dong B; Shen L; Ji J; Gao J; Zhang X
Cell Death Dis; 2018 Jan; 9(2):123. PubMed ID: 29374144
[TBL] [Abstract][Full Text] [Related]
4. Potential biomarkers for paclitaxel sensitivity in hypopharynx cancer cell.
Xu CZ; Shi RJ; Chen D; Sun YY; Wu QW; Wang T; Wang PH
Int J Clin Exp Pathol; 2013; 6(12):2745-56. PubMed ID: 24294361
[TBL] [Abstract][Full Text] [Related]
5. Activation of AKT/ERK confers non-small cell lung cancer cells resistance to vinorelbine.
Fan DP; Zhang YM; Hu XC; Li JJ; Zhang W
Int J Clin Exp Pathol; 2014; 7(1):134-43. PubMed ID: 24427333
[TBL] [Abstract][Full Text] [Related]
6. Exosomal miR-493 suppresses MAD2L1 and induces chemoresistance to intraperitoneal paclitaxel therapy in gastric cancer patients with peritoneal metastasis.
Makinoya M; Miyatani K; Matsumi Y; Sakano Y; Shimizu S; Shishido Y; Hanaki T; Kihara K; Matsunaga T; Yamamoto M; Tokuyasu N; Takano S; Sakamoto T; Hasegawa T; Saito H; Nakayama Y; Osaki M; Okada F; Fujiwara Y
Sci Rep; 2024 May; 14(1):10075. PubMed ID: 38698201
[TBL] [Abstract][Full Text] [Related]
7. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
8. Circular RNA circ-PVT1 contributes to paclitaxel resistance of gastric cancer cells through the regulation of ZEB1 expression by sponging miR-124-3p.
Liu YY; Zhang LY; Du WZ
Biosci Rep; 2019 Dec; 39(12):. PubMed ID: 31793989
[TBL] [Abstract][Full Text] [Related]
9. Genome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecin-resistant gastric cancer cells.
Wu XM; Shao XQ; Meng XX; Zhang XN; Zhu L; Liu SX; Lin J; Xiao HS
Acta Pharmacol Sin; 2011 Feb; 32(2):259-69. PubMed ID: 21293479
[TBL] [Abstract][Full Text] [Related]
10. Upregulation of miR-34c after silencing E2F transcription factor 1 inhibits paclitaxel combined with cisplatin resistance in gastric cancer cells.
Zheng H; Wang JJ; Yang XR; Yu YL
World J Gastroenterol; 2020 Feb; 26(5):499-513. PubMed ID: 32089626
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of paclitaxel-induced apoptosis in an ovarian cancer cell line and its paclitaxel-resistant clone.
Sugimura M; Sagae S; Ishioka S; Nishioka Y; Tsukada K; Kudo R
Oncology; 2004; 66(1):53-61. PubMed ID: 15031599
[TBL] [Abstract][Full Text] [Related]
12. RAF1-MEK1-ERK/AKT axis may confer NSCLC cell lines resistance to erlotinib.
Xu ZH; Hang JB; Hu JA; Gao BL
Int J Clin Exp Pathol; 2013; 6(8):1493-504. PubMed ID: 23923067
[TBL] [Abstract][Full Text] [Related]
13. miR-21 modulates cisplatin resistance of gastric cancer cells by inhibiting autophagy via the PI3K/Akt/mTOR pathway.
Gu Y; Fei Z; Zhu R
Anticancer Drugs; 2020 Apr; 31(4):385-393. PubMed ID: 31913198
[TBL] [Abstract][Full Text] [Related]
14. Demethylation of HIN-1 reverses paclitaxel-resistance of ovarian clear cell carcinoma through the AKT-mTOR signaling pathway.
Ho CM; Huang CJ; Huang SH; Chang SF; Cheng WF
BMC Cancer; 2015 Oct; 15():789. PubMed ID: 26497956
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel reversed trastuzumab resistance via regulating JUN in human gastric cancer cells identified by FAN analysis.
Wang Z; Zou F; Tian Y; Xiang B; Qin B; Liu Y
Future Oncol; 2018 Nov; 14(26):2701-2712. PubMed ID: 30265158
[TBL] [Abstract][Full Text] [Related]
16. Apatinib weakens resistance of gastric cancer cells to paclitaxel by suppressing JAK/STAT3 signaling pathway.
Bei Y; Chen X; Xu Q; Lv J; Hu J; Yang S
Drug Dev Res; 2022 Apr; 83(2):379-388. PubMed ID: 34405891
[TBL] [Abstract][Full Text] [Related]
17. RNA-seq reveals determinants of sensitivity to chemotherapy drugs in esophageal carcinoma cells.
Yang LX; Li BL; Liu XH; Yuan Y; Lu CJ; Chen R; Zhao J
Int J Clin Exp Pathol; 2014; 7(4):1524-33. PubMed ID: 24817948
[TBL] [Abstract][Full Text] [Related]
18. [Molecular mechanism of chemosensitization to paclitaxel in human melanoma cells induced by targeting the EGFR signaling pathway].
Zhang XJ; Zhang L; Liu YP; Xu HM; Sun P; Song JG; Luo YH
Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):181-6. PubMed ID: 23879997
[TBL] [Abstract][Full Text] [Related]
19. TWIST mediates resistance to paclitaxel by regulating Akt and Bcl-2 expression in gastric cancer cells.
Kwon CH; Park HJ; Choi Y; Won YJ; Lee SJ; Park DY
Tumour Biol; 2017 Oct; 39(10):1010428317722070. PubMed ID: 28982309
[TBL] [Abstract][Full Text] [Related]
20. Targeting of SPP1 by microRNA-340 inhibits gastric cancer cell epithelial-mesenchymal transition through inhibition of the PI3K/AKT signaling pathway.
Song SZ; Lin S; Liu JN; Zhang MB; Du YT; Zhang DD; Xu WH; Wang HB
J Cell Physiol; 2019 Aug; 234(10):18587-18601. PubMed ID: 30953349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
